BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 21134046)

  • 1. Comparison of two botulinum toxin type A preparations for treating crow's feet: a split-face, double-blind, proof-of-concept study.
    Prager W; Wissmüller E; Kollhorst B; Williams S; Zschocke I
    Dermatol Surg; 2010 Dec; 36 Suppl 4():2155-60. PubMed ID: 21134046
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of botulinum toxin type A in the treatment of lateral crow's feet: double-blind, placebo-controlled, dose-ranging study.
    Ascher B; Rzany BJ; Grover R
    Dermatol Surg; 2009 Oct; 35(10):1478-86. PubMed ID: 19686365
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A double-blind, randomized, placebo-controlled health-outcomes survey of the effect of botulinum toxin type a injections on quality of life and self-esteem.
    Dayan SH; Arkins JP; Patel AB; Gal TJ
    Dermatol Surg; 2010 Dec; 36 Suppl 4():2088-97. PubMed ID: 21070456
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety evaluation of a novel botulinum toxin topical gel for the treatment of moderate to severe lateral canthal lines.
    Brandt F; O'Connell C; Cazzaniga A; Waugh JM
    Dermatol Surg; 2010 Dec; 36 Suppl 4():2111-8. PubMed ID: 21134043
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bilateral, double-blind, randomized comparison of 3 doses of botulinum toxin type A and placebo in patients with crow's feet.
    Lowe NJ; Lask G; Yamauchi P; Moore D
    J Am Acad Dermatol; 2002 Dec; 47(6):834-40. PubMed ID: 12451366
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Noninferiority of incobotulinumtoxinA, free from complexing proteins, compared with another botulinum toxin type A in the treatment of glabellar frown lines.
    Sattler G; Callander MJ; Grablowitz D; Walker T; Bee EK; Rzany B; Flynn TC; Carruthers A
    Dermatol Surg; 2010 Dec; 36 Suppl 4():2146-54. PubMed ID: 21134045
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intraoperative injection of botulinum toxin A into the orbicularis oculi muscle for the treatment of crow's feet.
    Guerrissi JO
    Plast Reconstr Surg; 2003 Oct; 112(5 Suppl):161S-163S. PubMed ID: 14504499
    [No Abstract]   [Full Text] [Related]  

  • 8. Efficacy and Safety of Prabotulinumtoxin A and Onabotulinumtoxin A for Crow's Feet: A Phase 3, Multicenter, Randomized, Double-Blind, Split-Face Study.
    Cheon HI; Jung N; Won CH; Kim BJ; Lee YW
    Dermatol Surg; 2019 Dec; 45(12):1610-1619. PubMed ID: 30893169
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dosing, efficacy and safety plus the use of computerized photography for botulinum toxins type A for upper facial lines.
    Lowe NJ; Shah A; Lowe PL; Patnaik R
    J Cosmet Laser Ther; 2010 Apr; 12(2):106-11. PubMed ID: 20151785
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Double-blind, randomized, placebo-controlled, dose-response study of the safety and efficacy of botulinum toxin type A in subjects with crow's feet.
    Lowe NJ; Ascher B; Heckmann M; Kumar C; Fraczek S; Eadie N;
    Dermatol Surg; 2005 Mar; 31(3):257-62. PubMed ID: 15841623
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Facial rejuvenation after intradermal botulinum toxin: is it really the botulinum toxin or is it the pricks?
    Kapoor R; Shome D; Jain V; Dikshit R
    Dermatol Surg; 2010 Dec; 36 Suppl 4():2098-105. PubMed ID: 21134041
    [TBL] [Abstract][Full Text] [Related]  

  • 12. OnabotulinumtoxinA treatment of mild glabellar lines in repose.
    Carruthers A; Carruthers J; Lei X; Pogoda JM; Eadie N; Brin MF
    Dermatol Surg; 2010 Dec; 36 Suppl 4():2168-71. PubMed ID: 21134048
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Botulinum toxin type a for facial rejuvenation: treatment evolution and patient satisfaction.
    Sepehr A; Chauhan N; Alexander AJ; Adamson PA
    Aesthetic Plast Surg; 2010 Oct; 34(5):583-6. PubMed ID: 20383497
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Remodeling of periorbital, temporal, glabellar, and crow's feet areas with hyaluronic acid and botulinum toxin.
    Beer KR; Julius H; Dunn M; Wilson F
    J Cosmet Dermatol; 2014 Jun; 13(2):143-50. PubMed ID: 24910278
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multicenter, randomized, parallel-group study of the safety and effectiveness of onabotulinumtoxinA and hyaluronic acid dermal fillers (24-mg/ml smooth, cohesive gel) alone and in combination for lower facial rejuvenation.
    Carruthers A; Carruthers J; Monheit GD; Davis PG; Tardie G
    Dermatol Surg; 2010 Dec; 36 Suppl 4():2121-34. PubMed ID: 21134044
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A double-blinded, randomized, placebo-controlled pilot study of the safety and efficacy of Myobloc (botulinum toxin type B)-purified neurotoxin complex for the treatment of crow's feet: a double-blinded, placebo-controlled trial.
    Baumann L; Slezinger A; Vujevich J; Halem M; Bryde J; Black L; Duncan R
    Dermatol Surg; 2003 May; 29(5):508-15. PubMed ID: 12752519
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Prospective, Neurophysiologic Comparative Study to Assess the Efficacy and Duration of Effect of IncobotulinumtoxinA and AbobotulinumtoxinA in the Treatment of Crow's Feet.
    Saybel A; Artemenko A; Nikitin S; Kurenkov A
    J Drugs Dermatol; 2015 Nov; 14(11):1291-6. PubMed ID: 26580879
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Botulinum toxin type A treatment of multiple upper facial sites: patient-reported outcomes.
    Carruthers J; Carruthers A
    Dermatol Surg; 2007 Jan; 33(1 Spec No.):S10-7. PubMed ID: 17241408
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clostridium botulinum type A toxin for the treatment of upper face animation lines: an Iranian experience.
    Farahvash MR; Arad S
    J Cosmet Dermatol; 2007 Sep; 6(3):152-8. PubMed ID: 17760691
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Botulinum toxin types A and B: comparison of efficacy, duration, and dose-ranging studies for the treatment of facial rhytides and hyperhidrosis.
    Yamauchi PS; Lowe NJ
    Clin Dermatol; 2004; 22(1):34-9. PubMed ID: 15158543
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.